Company Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Real-time Estimate Cboe Europe 11:09:35 2024-03-28 am EDT 5-day change 1st Jan Change
334.2 GBX +1.27% Intraday chart for Haleon plc +2.96% +3.72%

Business Summary

Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows:

- oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.;

- Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.;

- medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.;

- respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.;

- vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.

Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).

Number of employees: 25,408

Sales per Business

GBP in Million2022Weight2023Weight Delta
Oral Health
27.7 %
2,957 27.2 % 3,136 27.7 % +6.05%
Pain Relief
23.5 %
2,551 23.5 % 2,652 23.5 % +3.96%
Digestive Health and Other
18.9 %
2,096 19.3 % 2,138 18.9 % +2.00%
Respiratory Health
15.4 %
1,579 14.5 % 1,736 15.4 % +9.94%
Vitamins, Minerals and Supplements
14.5 %
1,675 15.4 % 1,640 14.5 % -2.09%

Sales per region

GBP in Million2022Weight2023Weight Delta
EMEA and Latin America
40.2 %
4,270 39.3 % 4,545 40.2 % +6.44%
North America
37.1 %
4,116 37.9 % 4,195 37.1 % +1.92%
APAC
22.7 %
2,472 22.8 % 2,562 22.7 % +3.64%

Managers

Managers TitleAgeSince
Chief Executive Officer 57 21-07-21
Director of Finance/CFO 52 21-11-30
Chief Tech/Sci/R&D Officer - 21-12-15
Investor Relations Contact - -
Sales & Marketing - 21-12-15
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Human Resources Officer - 22-02-28
General Counsel 57 21-12-15

Members of the board

Members of the board TitleAgeSince
Director/Board Member - 22-07-17
Director/Board Member 63 22-07-17
Director/Board Member 57 22-07-17
Director/Board Member 69 22-07-17
Director/Board Member 61 22-07-17
Chairman 59 22-05-22
Director/Board Member 59 23-02-28
Director of Finance/CFO 52 21-11-30
Chief Executive Officer 57 21-07-21
Director/Board Member - 22-07-17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 9,132,301,104 6,480,785,201 ( 70.97 %) 0 70.97 %

Shareholders

NameEquities%Valuation
2,062,236,079 22.33 % 8 646 M p
GSK PLC
4.173 %
385,320,110 4.173 % 1 616 M p
MFS International (UK) Ltd.
1.342 %
123,903,066 1.342 % 519 M p
abrdn Alternative Investments Ltd.
0.2697 %
24,901,236 0.2697 % 104 M p
Wellington Management International Ltd.
0.2668 %
24,635,760 0.2668 % 103 M p
Swedbank Robur Fonder AB
0.1958 %
18,078,365 0.1958 % 76 M p
Liontrust Portfolio Management Ltd.
0.1958 %
18,076,796 0.1958 % 76 M p
State Street Global Advisors Ltd.
0.1588 %
14,663,360 0.1588 % 61 M p
Aristotle Capital Management LLC
0.1574 %
14,535,482 0.1574 % 61 M p
Mediolanum International Funds Ltd.
0.1049 %
9,690,098 0.1049 % 41 M p
NameEquities%Valuation
Dodge & Cox
2.397 %
110,663,098 2.397 % 947 M p
Fidelity Management & Research Co. LLC
1.384 %
63,897,244 1.384 % 547 M p
ClearBridge Investments LLC
0.5757 %
26,581,902 0.5757 % 228 M p
Harding Loevner LP
0.4845 %
22,372,190 0.4845 % 192 M p
Fisher Asset Management LLC
0.3192 %
14,737,776 0.3192 % 126 M p
Wellington Management Co. LLP
0.2933 %
13,542,346 0.2933 % 116 M p
AllianceBernstein LP
0.2369 %
10,939,898 0.2369 % 94 M p
Aristotle Capital Management LLC
0.1929 %
8,905,038 0.1929 % 76 M p
Merrill Lynch International
0.1822 %
8,414,511 0.1822 % 72 M p
Douglas Lane & Associates LLC
0.1782 %
8,226,794 0.1782 % 70 M p

Company contact information

Haleon Plc

The Heights Building 5, 1st Floor

KT13 0NY, Weybridge

+44 1932 822000

http://www.haleon.com
address Haleon plc(HLN)

Group companies

NameCategory and Sector
Pharmaceuticals: Major
Financial Conglomerates
Financial Conglomerates
Financial Conglomerates
Drugstore Chains
Medical/Nursing Services
Regional Banks
Pharmaceuticals: Other

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
3.3 GBP
Average target price
3.608 GBP
Spread / Average Target
+9.34%
Consensus